Baidu
map

Hum Cell:ADRB2能够抑制miR-15a-5p调控的IL-13诱导的过敏性鼻炎炎症细胞因子

2019-05-25 AlexYang MedSci原创

过敏性鼻炎(AR)是一种常见的过敏性疾病,给患者带来很多的麻烦。鼻粘膜上皮细胞(NECs)是最外层的吸入保护层,在AR过敏反应中具有重要的作用。β肾上腺素能受体2(ADRB2)在炎症响应中是一个重要的基因,最近这些年已经成为了AR发展和治疗的关注焦点。miR-15a-5p已被证明参与了AR免疫响应,并且是ADRB2的上游调控因子。最近,有研究人员发现,ADRB2在AR患者的鼻粘膜中高表达,并且与I

过敏性鼻炎(AR)是一种常见的过敏性疾病,给患者带来很多的麻烦。鼻粘膜上皮细胞(NECs)是最外层的吸入保护层,在AR过敏反应中具有重要的作用。β肾上腺素能受体2(ADRB2)在炎症响应中是一个重要的基因,最近这些年已经成为了AR发展和治疗的关注焦点。miR-15a-5p已被证明参与了AR免疫响应,并且是ADRB2的上游调控因子。

最近,有研究人员发现,ADRB2在AR患者的鼻粘膜中高表达,并且与IL-13的刺激呈现正相关关系,ADRB2的敲除能够抑制IL-13诱导的GM-CSF、嗜酸细胞活化趋化因子和MUC5AC在NECs中的表达。另外,ADRB2可以直接被miR-15a-5p靶定,且miR-15a-5p能够抑制IL-13诱导的GM-CSF、嗜酸细胞活化趋化因子和MUC5AC在NECs中的表达。ADRB2还能调控miR-15a-5p对鼻上皮免疫响应的调节。

最后,研究人员指出,miR-15a-5p能够负调控ADRB2,也能够抑制IL-13诱导的鼻上皮炎症响应。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1809590, encodeId=6eaa180959032, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Fri Feb 21 00:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053608, encodeId=5408205360845, content=<a href='/topic/show?id=f84e6e055ab' target=_blank style='color:#2F92EE;'>#炎症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67055, encryptionId=f84e6e055ab, topicName=炎症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Feb 28 17:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047122, encodeId=2f6f204e122ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 02 05:06:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930710, encodeId=3fe01930e1077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 04 20:06:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961569, encodeId=d55f1961569b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 24 05:06:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871286, encodeId=e4be18e12866a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 13 19:06:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283624, encodeId=f5231283624aa, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508238, encodeId=7025150823823, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366833, encodeId=4e35366833b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 26 20:49:33 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1809590, encodeId=6eaa180959032, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Fri Feb 21 00:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053608, encodeId=5408205360845, content=<a href='/topic/show?id=f84e6e055ab' target=_blank style='color:#2F92EE;'>#炎症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67055, encryptionId=f84e6e055ab, topicName=炎症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Feb 28 17:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047122, encodeId=2f6f204e122ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 02 05:06:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930710, encodeId=3fe01930e1077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 04 20:06:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961569, encodeId=d55f1961569b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 24 05:06:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871286, encodeId=e4be18e12866a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 13 19:06:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283624, encodeId=f5231283624aa, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508238, encodeId=7025150823823, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366833, encodeId=4e35366833b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 26 20:49:33 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1809590, encodeId=6eaa180959032, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Fri Feb 21 00:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053608, encodeId=5408205360845, content=<a href='/topic/show?id=f84e6e055ab' target=_blank style='color:#2F92EE;'>#炎症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67055, encryptionId=f84e6e055ab, topicName=炎症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Feb 28 17:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047122, encodeId=2f6f204e122ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 02 05:06:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930710, encodeId=3fe01930e1077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 04 20:06:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961569, encodeId=d55f1961569b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 24 05:06:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871286, encodeId=e4be18e12866a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 13 19:06:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283624, encodeId=f5231283624aa, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508238, encodeId=7025150823823, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366833, encodeId=4e35366833b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 26 20:49:33 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1809590, encodeId=6eaa180959032, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Fri Feb 21 00:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053608, encodeId=5408205360845, content=<a href='/topic/show?id=f84e6e055ab' target=_blank style='color:#2F92EE;'>#炎症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67055, encryptionId=f84e6e055ab, topicName=炎症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Feb 28 17:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047122, encodeId=2f6f204e122ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 02 05:06:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930710, encodeId=3fe01930e1077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 04 20:06:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961569, encodeId=d55f1961569b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 24 05:06:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871286, encodeId=e4be18e12866a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 13 19:06:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283624, encodeId=f5231283624aa, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508238, encodeId=7025150823823, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366833, encodeId=4e35366833b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 26 20:49:33 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
    2019-06-04 smallant2002
  5. [GetPortalCommentsPageByObjectIdResponse(id=1809590, encodeId=6eaa180959032, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Fri Feb 21 00:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053608, encodeId=5408205360845, content=<a href='/topic/show?id=f84e6e055ab' target=_blank style='color:#2F92EE;'>#炎症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67055, encryptionId=f84e6e055ab, topicName=炎症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Feb 28 17:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047122, encodeId=2f6f204e122ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 02 05:06:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930710, encodeId=3fe01930e1077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 04 20:06:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961569, encodeId=d55f1961569b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 24 05:06:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871286, encodeId=e4be18e12866a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 13 19:06:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283624, encodeId=f5231283624aa, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508238, encodeId=7025150823823, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366833, encodeId=4e35366833b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 26 20:49:33 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
    2019-12-24 维他命
  6. [GetPortalCommentsPageByObjectIdResponse(id=1809590, encodeId=6eaa180959032, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Fri Feb 21 00:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053608, encodeId=5408205360845, content=<a href='/topic/show?id=f84e6e055ab' target=_blank style='color:#2F92EE;'>#炎症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67055, encryptionId=f84e6e055ab, topicName=炎症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Feb 28 17:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047122, encodeId=2f6f204e122ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 02 05:06:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930710, encodeId=3fe01930e1077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 04 20:06:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961569, encodeId=d55f1961569b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 24 05:06:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871286, encodeId=e4be18e12866a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 13 19:06:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283624, encodeId=f5231283624aa, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508238, encodeId=7025150823823, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366833, encodeId=4e35366833b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 26 20:49:33 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1809590, encodeId=6eaa180959032, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Fri Feb 21 00:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053608, encodeId=5408205360845, content=<a href='/topic/show?id=f84e6e055ab' target=_blank style='color:#2F92EE;'>#炎症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67055, encryptionId=f84e6e055ab, topicName=炎症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Feb 28 17:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047122, encodeId=2f6f204e122ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 02 05:06:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930710, encodeId=3fe01930e1077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 04 20:06:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961569, encodeId=d55f1961569b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 24 05:06:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871286, encodeId=e4be18e12866a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 13 19:06:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283624, encodeId=f5231283624aa, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508238, encodeId=7025150823823, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366833, encodeId=4e35366833b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 26 20:49:33 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1809590, encodeId=6eaa180959032, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Fri Feb 21 00:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053608, encodeId=5408205360845, content=<a href='/topic/show?id=f84e6e055ab' target=_blank style='color:#2F92EE;'>#炎症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67055, encryptionId=f84e6e055ab, topicName=炎症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Feb 28 17:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047122, encodeId=2f6f204e122ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 02 05:06:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930710, encodeId=3fe01930e1077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 04 20:06:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961569, encodeId=d55f1961569b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 24 05:06:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871286, encodeId=e4be18e12866a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 13 19:06:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283624, encodeId=f5231283624aa, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508238, encodeId=7025150823823, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366833, encodeId=4e35366833b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 26 20:49:33 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
    2019-05-27 jjjiang0202
  9. [GetPortalCommentsPageByObjectIdResponse(id=1809590, encodeId=6eaa180959032, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Fri Feb 21 00:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053608, encodeId=5408205360845, content=<a href='/topic/show?id=f84e6e055ab' target=_blank style='color:#2F92EE;'>#炎症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67055, encryptionId=f84e6e055ab, topicName=炎症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Fri Feb 28 17:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047122, encodeId=2f6f204e122ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 02 05:06:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930710, encodeId=3fe01930e1077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 04 20:06:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961569, encodeId=d55f1961569b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Dec 24 05:06:00 CST 2019, time=2019-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871286, encodeId=e4be18e12866a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 13 19:06:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283624, encodeId=f5231283624aa, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508238, encodeId=7025150823823, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Mon May 27 13:06:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366833, encodeId=4e35366833b3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 26 20:49:33 CST 2019, time=2019-05-26, status=1, ipAttribution=)]
    2019-05-26 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Am J Rhinol Allergy:非过敏性鼻炎患者的临床特性区分

并不是所有的鼻炎患者均受免疫球蛋白E(lgE)调控的炎症过程影响。由于皮刺和血清过敏原评估受限,因而不能对局部过敏性鼻炎(LAR)进行确诊。因此,具有阴性系统性过敏评估的患者其实包括了非过敏性鼻炎患者(NAR)和LAR患者。最近,有研究人员确定了NAR患者的临床特性。研究是一个代表性的研究,包括了154名参与者(平均年龄为41.79±14.78岁,37.7%的为女性 )。与AR患者相比,NAR患者

Allergy Asthma Proc:奥洛他定-莫米松组合鼻喷剂在季节过敏性鼻炎患者中的效果和安全性评估

GSP301是一种研究用的固定剂量组合鼻喷剂,其中包含了抗组胺剂、盐酸洛普他定(HCI)和皮质类固醇糠酸莫米他松。最近,有研究人员评估了GSP301在季节过敏性鼻炎(SAR)患者中的效果和安全性。研究是一个双盲、随机和平行的研究。研究总共包括了1180名患者。在经过14天的治疗后,与安慰剂组(最小平方平均差-0.98;95%CI,-1.38到-0.57;p<0.001)和奥洛他定治疗组(p=

EBioMedicine:IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关

自身免疫和过敏与调节T细胞(Tregs)数目的减少和低水平的白介素-2(IL-2)相关。最近,有研究人员调查了在童年早期,是否病原气道细菌刺激外周血单核细胞(PBMCs)而释放的IL-2与过敏结果的发展相关。研究人员从331名6月大的婴幼儿中分离了PBMCs细胞,之后在体外利用流感嗜血杆菌、卡他拉氏杆菌和肺炎链球菌对PBMCs细胞进行刺激。之后,利用电化学荧光免疫反应对各种细胞因子(IL-2, I

盘点:鼻炎研究小结

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与大家一起分享学习!【1】Clin Exp Otorhinolaryngol:长期母乳喂养在预防过敏性鼻炎中的作用分析 https://www.ncbi.nlm.nih.gov/pubmed/309

盘点:鼻炎治疗研究小结

【1】Clin Exp Otorhinolaryngol:虎耳草在过敏性鼻炎中的抗过敏作用研究 https://www.ncbi.nlm.nih.gov/pubmed/30942049虎耳草提取物具有抗癌、抗过敏和抗氧化活性。最近,有研究人员调查了虎耳草提取物对过敏性鼻炎炎症中的作用。研究包括了4个不同的小组(组A:对照组;组B:过敏性鼻炎组;组C:300mg/kg处理组;组D:600mg/k

Int Arch Allergy Immunol:过敏性鼻炎和哮喘的尘螨属螨虫敏感的分布的决定因素分析

过敏原免疫治疗(AIT)需要知道过敏原的分布信息,从而来鉴定AIT使用的高风险区域。然而,虽然尘螨属过敏原的流行率越来越高,这些过敏原在中国的地理分布模式仍旧不清楚。研究人员回顾了163篇文章,这些文章包括了阳性过敏原的案例,研究人员利用这些信息产生了过敏原分布图。研究人员发现,屋尘螨和粉尘螨敏感的比例在过敏性鼻炎(AR)患者中的分布相似(75.1 vs. 75.2%, p>0.05),但是

Baidu
map
Baidu
map
Baidu
map